Calocurb entered the US as a DTC supplement in 2018 and spent six years proving the product worked. The decision that actually built the business came in 2024 — and it’s the one most NZ founders never make.
The science was always the moat. The 2024 decision was the moment the distribution architecture finally reflected that.
— Sean McGrail, PIVOTAL CATALYST
Founded 2017, Auckland, New Zealand, commercialising research begun in 2010 by Plant & Food Research. Product: Calocurb is a patented dietary supplement containing Amarasate — a standardised extract of NZ-grown hops that activates bitter taste receptors in the small intestine, triggering the body’s own release of satiety hormones including GLP-1, CCK, and peptide YY. The mechanism is called the “bitter brake.” The product is encapsulated in a patented delayed-release Licaps capsule manufactured by Lonza in South Carolina to ensure delivery to the duodenum rather than the stomach.
The domestic NZ market was never the commercial thesis — New Zealand’s supplement market is too small to justify the $30M+ in upstream research investment. The US was always the primary target. Revenue at US entry was below $1M in 2018/2019 — the company was pre-revenue in any meaningful sense: a science project with a Shopify store. The GLP-1 pharmaceutical revolution changed everything. When Ozempic and Wegovy entered mass-market awareness in 2022–2023, Novo Nordisk’s marketing spend effectively educated the entire US public on why hunger is hormonal. Calocurb had a natural, non-injectable product that activated the same hormonal pathway. The market had just been built for them by a competitor with a $4 billion marketing budget.
The strategic rationale was unusually clean for a NZ founder taking a science-led product into a large, competitive market. Three components, all correct. First: the GLP-1 pharmaceutical market was creating a new category of consumer who understood that hunger was a hormonal event, not a willpower failure — and the cost of that category education had been paid by Novo Nordisk, not Calocurb. Second: the US regulatory environment under DSHEA was genuinely favourable. A supplement with GRAS status can be marketed without the decade-long drug approval process — the same product in a pharmaceutical regulatory context would have required another eight to twelve years and several hundred million dollars. Third: the IP moat was real. The Amarasate extract is patented. The delayed-release delivery mechanism is patented. Fourteen years of research produced a defensible position that no competitor can replicate cheaply.
The thesis was sound. What was not sound was the channel architecture that executed it — and the correction of that architecture is what made the difference.
2018: US launch via Shopify DTC. Top 1% of web traffic among 2,500 global Shopify store launches on day one. Conversion rate four times the global average. 2022–2023: GLP-1 pharmaceutical wave. Calocurb pivots messaging to “natural GLP-1 alternative,” rides media wave as the credible non-injectable alternative. Significant PR coverage. Cancelled $10M Series A round (reported by PitchBook) at some point during this period. 2024: Partnership with Ortho Molecular Products, a US-based manufacturer distributing exclusively to healthcare practitioners. Launch of “Calocurb Clinical” at 250mg (double the retail dose), $119.99/month, practitioner-only. Revenue doubles to over $10M. Wins American Chamber of Commerce “Exporter of the Year to the US” in consumer goods.
Unlike most teardowns, this is not a story of four mistakes that compounded into failure. This is a story of three decisions — two that were correct but limited, and one that changed the trajectory entirely.
Calocurb launched in the US as a direct-to-consumer brand via Shopify and the initial results were exceptional — top 1% for web traffic and sales among 2,500 global Shopify store launches on day one, with conversion rates four times the global average. For a NZ science brand entering the US with no distributor and no US marketing infrastructure, those numbers were genuinely remarkable. They were also the ceiling of what the DTC model could produce.
US health and wellness DTC runs at $80–$150 CAC. Calocurb retails at $80–90/month. At the low end of US supplement CAC, the first purchase is breakeven. At the high end, it’s a loss. Revenue grew, but growth was capped by the economics of paid acquisition in a crowded channel. The brand had exceptional initial conversion — which is a product and messaging strength — but DTC alone could not produce the volume required to justify the upstream scientific investment or reach the customer segments most likely to sustain long-term use.
From 2022 onward, Calocurb leaned hard into positioning as a natural GLP-1 alternative. The messaging — activating the same hormonal pathway without a needle, without a prescription, and without the $1,000+ monthly cost of Wegovy — was accurate, differentiated, and riding one of the largest consumer health waves in a generation. CEO Sarah Kennedy became a media presence across podcasts and health platforms as the credible alternative to pharmaceutical weight management.
The strategic gap: the “natural GLP-1 alternative” framing raised the clinical credibility bar. A consumer who had read about Ozempic wanted to know whether their doctor knew about Calocurb. Most US primary care physicians did not. The DTC brand-building was reaching the consumer without reaching the clinician who would ultimately validate or dismiss the purchase for the highest-value customer segments. Calocurb had four human clinical trials and peer-reviewed data — but that evidence was not reaching the clinical decision-maker. The science existed. The channel to the clinician did not.
In 2024, Calocurb partnered with Ortho Molecular Products — a US-based manufacturer distributing exclusively to healthcare practitioners, not retail. The partnership produced “Calocurb Clinical”: a 250mg Amarasate formulation (double the retail dose), priced at $119.99/month and available only through licensed practitioners. Entering the practitioner channel required building a fundamentally different commercial infrastructure — clinical sales materials, practitioner education programs, a phased onboarding dosing protocol, and a pricing architecture supporting practitioner margins without destroying the retail product’s positioning.
It also required acknowledging that the DTC channel, which had been the entire US business model for six years, was not going to produce the scale needed. Most founders do not make that acknowledgement until DTC is visibly failing. Calocurb made it while DTC was still growing. The practitioner channel transforms customer acquisition economics entirely. A healthcare practitioner recommending Calocurb to ten patients per month is a recurring revenue node, not a one-time acquisition. The GLP-1 “off-ramp” use case — practitioners using Calocurb to manage hunger rebound in patients tapering off semaglutide — created a clinical application no DTC brand can compete for. Revenue doubled to over $10M following the partnership. That is not a coincidence of timing.
The Ortho Molecular partnership was not the obvious move. Entering a practitioner-only distribution channel from a DTC foundation required accepting that the existing customer acquisition model could not scale to the revenue target. The near-miss is worth naming. The cancelled $10M Series A round suggests that at some point, a capital raise that would have accelerated scale did not close. A company that cannot close its Series A and is operating primarily through DTC in one of the most crowded consumer supplement markets on the planet is not in a stable position. The Ortho Molecular partnership arrived at a moment when the alternative — continuing to compete on DTC acquisition economics against better-funded US brands — was not a long-term strategy. It was the right decision. It also may have been the necessary one.
What they got right: the upstream work. Fourteen years of research, four clinical trials, a defensible patent portfolio, GRAS status, and a manufacturing partnership with Lonza that satisfies FDA GMP requirements. This is not the foundation most NZ supplement brands bring to the US market. It is exceptional — and it is what made the 2024 channel pivot possible. You cannot enter the Ortho Molecular practitioner channel with anecdotal evidence and a Shopify store. Calocurb earned that channel with evidence most competitors cannot produce.
The one structural decision that determined the outcome: the practitioner channel pivot in 2024. Not because DTC was failing — it wasn’t — but because the practitioner channel was the only distribution architecture that could match the clinical evidence the company had built. The science was always the moat. The 2024 decision was the moment the distribution architecture finally reflected that. A properly architected US entry would have used DTC as market validation — not the long-term revenue model — and built the Ortho Molecular-type partnership from year two or three, not year six.
If your product has genuine clinical evidence, your DTC brand is the wrong primary channel — it’s the right proof-of-concept. A consumer encountering a supplement through a paid ad applies the same credibility filter to your peer-reviewed trial data as they apply to a claim on a protein bar. The clinical evidence does not survive the consumer credibility environment. If you have real science, the channel that can evaluate it is a practitioner, a clinical buyer, or an institutional purchaser — not someone on Instagram. Build the DTC channel to demonstrate product-market fit. Build the practitioner channel to generate revenue that reflects the actual value of what you’ve built.
When a competitor with a $4 billion marketing budget enters your category, the correct response is to become their off-ramp, not their competitor. Calocurb could not outspend Novo Nordisk. What they could do was become the product practitioners reached for when patients needed to come off semaglutide. The “GLP-1 off-ramp” positioning is a structural advantage that pharmaceutical companies cannot occupy because they cannot sell a natural supplement, and that other supplement brands cannot occupy because they do not have the clinical evidence.
The practitioner channel compounds. The paid acquisition channel does not. A DTC customer acquired through paid advertising has an acquisition cost that resets every time you need a new customer. A practitioner who recommends your product has an acquisition cost that amortises across every patient they see for the duration of the clinical relationship. For a NZ company with a high-cost, science-intensive product, the compounding channel is the only model that produces the margins to justify the upstream investment.
Calocurb got the science right from the beginning. What took six years to correct was the commercial architecture that matched the science to the right buyer. The DTC launch validated the product. The Ortho Molecular partnership validated the business model. Most NZ founders never reach the second validation because they treat the first one as the answer.
Your US expansion plan is built around a channel. The US Entry Diagnostic identifies the structural question that channel cannot answer — not to tell you the channel is wrong, but to tell you what you don’t yet know about whether it’s right. Calocurb had the clinical evidence. The question was always which channel could monetise it. That question has a specific answer for your business too.
THE CHANNEL INFLECTION
Revenue doubled to over $10M in the year Calocurb entered the Ortho Molecular practitioner channel
Six years of DTC growth didn’t produce it. One channel pivot — matching the clinical evidence to the buyer who could evaluate it — did.
DECISION QUALITY ANALYSIS — CALOCURB
FREQUENTLY ASKED
Why do NZ science-led companies struggle to scale in the US despite strong clinical evidence?
Clinical evidence is a channel-specific asset. In a consumer DTC environment, peer-reviewed trial data competes with marketing claims from thousands of competitors and rarely survives the scroll. In a practitioner channel, the same data is the primary sales tool. Most NZ science-led brands build consumer channels without building clinical distribution, which means the evidence they’ve spent years and millions generating never reaches the buyer who can evaluate it correctly.
What made Calocurb’s US expansion succeed when comparable supplement brands failed?
Three things worked together: a defensible patent that prevented fast-follower competition; a timing decision to ride the GLP-1 pharmaceutical wave rather than resist it; and the 2024 pivot into the Ortho Molecular practitioner channel, which matched the clinical evidence to a distribution architecture that could monetise it. Remove any one of those three and the outcome changes.
How should a NZ health or wellness company think about US channel strategy at market entry?
Start by identifying who can evaluate your evidence correctly — consumer, practitioner, or institutional buyer — and build the channel that reaches them first. DTC is the fastest channel to test product-market fit. It is rarely the most capital-efficient channel to scale a science-led product. If your product has clinical backing, the practitioner channel will almost always produce better unit economics and lower churn than paid digital acquisition.
YOUR US ENTRY PLAN HAS A CHANNEL ARCHITECTURE
The US Entry Diagnostic identifies the structural question your current channel cannot answer — not to tell you it’s wrong, but to tell you what you don’t yet know about whether it’s right. Calocurb had the clinical evidence. The question was which channel could monetise it. That question has a specific answer for your business too.
Book the US Entry Diagnostic$10,000 NZD. Credited in full toward any engagement. Go in knowing.